MYCO-005 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and anxiety disorders.
It is a tryptamine derivative and an analogue of psilocin. However, whereas psilocin and other tryptamines show high affinity for and potent activation of not only the serotonin 5-HT2A receptor but also the serotonin 5-HT2B receptor, MYCO-005 does not bind to this receptor. Activation of the serotonin 5-HT2B receptor is known to induce the development of cardiac valvulopathy and has been a concern with regard to chronic microdosing of psychedelics. Since MYCO-005 does not activate the serotonin 5-HT2B receptor, it is anticipated to be heart-safe and to be safer for use in the contexts of both macro- and microdosing than other psychedelics.
As of February 2024, MYCO-005 is in the research stage of development for depressive disorders and anxiety disorders. It is being developed by Mydecine. The exact chemical structure of MYCO-005 does not yet seem to have been disclosed. However, the compound was patented in 2023 and the specified patent specifically describes aza-substituted psilocin analogues.
No More Posts Available.
No more pages to load.
